• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤的临床、实验室、组织学、影像学和代谢特征及预后

Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.

机构信息

Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

Department of Respiratory and Critical Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

出版信息

Medicina (Kaunas). 2022 Dec 19;58(12):1874. doi: 10.3390/medicina58121874.

DOI:10.3390/medicina58121874
PMID:36557076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9785569/
Abstract

Malignant pleural mesothelioma (MPM) is an aggressive and rare malignant pleural tumor. MPM patients diagnosed in Beijing Chaoyang Hospital and Beijing Tongren Hospital were the focus of this study. We collected and analyzed the histological, radiological, and metabolic features of MPM patients. At the same time, Cox univariable and multivariable analyses were used to explore the laboratory risk factors affecting the prognosis of MPM patients. A total of 129 MPM patients were included in this study. MPM includes three main histological subtypes: epithelioid, sarcomatoid and biphasic. Among them, epithelial subtypes accounted for the highest proportion. Calretinin, Wilms' tumor gene (WT1), cytokeratin 5/6 (CK5/6), and D2-40 were the most useful mesothelial markers to support a MPM diagnosis. The imaging features of MPM patients are pleural thickening and pleural effusion. In PET-CT, the affected pleura showed obvious high uptake of tracer, and the degree was related to the specific subtype. The median follow-up time was 55.0 (30.0, 94.0) months. A total of 92 (71.3%) patients died during follow-up. The median survival time of patients was 21.0 (9.0, 48.0) months. The Cox multivariable analysis showed that age [hazard ratio (HR), 1.824; 95% confidence interval (CI) 1.159-2.872; = 0.009; uncorrected], ESR (HR, 2.197; 95% CI 1.318-3.664; = 0.003; with Bonferroni correction), lymphocytes (HR, 0.436; 95% CI 0.258-0.737; = 0.002; with Bonferroni correction), platelets (HR, 1.802; 95% CI 1.084-2.997; = 0.023; uncorrected) and total protein (HR, 0.625; 95% CI 0.394-0.990; = 0.045; uncorrected) were independent risk factors for prognosis, after adjusting for confounding factors. Age, ESR, lymphocytes, platelets and total protein may be related to the prognosis of MPM patients. Summarizing the histological, radiological, and metabolic features of MPM patients in the two centers can increase clinicians' understanding of this rare tumor.

摘要

恶性胸膜间皮瘤(MPM)是一种侵袭性和罕见的恶性胸膜肿瘤。本研究的重点是在北京朝阳医院和北京同仁医院诊断的 MPM 患者。我们收集和分析了 MPM 患者的组织学、影像学和代谢特征。同时,采用 Cox 单变量和多变量分析探讨影响 MPM 患者预后的实验室危险因素。本研究共纳入 129 例 MPM 患者。MPM 包括三种主要的组织学亚型:上皮样、肉瘤样和双相型。其中,上皮亚型占比最高。钙视网膜蛋白、Wilms 瘤基因(WT1)、细胞角蛋白 5/6(CK5/6)和 D2-40 是最有助于支持 MPM 诊断的间皮标志物。MPM 患者的影像学特征为胸膜增厚和胸腔积液。在 PET-CT 中,受累胸膜显示明显的示踪剂摄取增高,程度与特定亚型有关。中位随访时间为 55.0(30.0,94.0)个月。随访期间共有 92 例(71.3%)患者死亡。患者中位生存时间为 21.0(9.0,48.0)个月。Cox 多变量分析显示,年龄[风险比(HR),1.824;95%置信区间(CI)1.159-2.872; = 0.009;未校正]、ESR(HR,2.197;95% CI 1.318-3.664; = 0.003;校正 Bonferroni 后)、淋巴细胞(HR,0.436;95% CI 0.258-0.737; = 0.002;校正 Bonferroni 后)、血小板(HR,1.802;95% CI 1.084-2.997; = 0.023;未校正)和总蛋白(HR,0.625;95% CI 0.394-0.990; = 0.045;未校正)是预后的独立危险因素,在调整混杂因素后。年龄、ESR、淋巴细胞、血小板和总蛋白可能与 MPM 患者的预后相关。总结两个中心 MPM 患者的组织学、影像学和代谢特征,可以增加临床医生对这种罕见肿瘤的认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/4589f8cdcf27/medicina-58-01874-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/bc3436b1f262/medicina-58-01874-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/b9fd8f7e9edf/medicina-58-01874-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/f74ef134ca32/medicina-58-01874-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/c51bc23f3cb7/medicina-58-01874-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/8e6305af01b9/medicina-58-01874-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/083f8d07e7a4/medicina-58-01874-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/4589f8cdcf27/medicina-58-01874-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/bc3436b1f262/medicina-58-01874-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/b9fd8f7e9edf/medicina-58-01874-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/f74ef134ca32/medicina-58-01874-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/c51bc23f3cb7/medicina-58-01874-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/8e6305af01b9/medicina-58-01874-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/083f8d07e7a4/medicina-58-01874-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fa/9785569/4589f8cdcf27/medicina-58-01874-g007.jpg

相似文献

1
Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的临床、实验室、组织学、影像学和代谢特征及预后
Medicina (Kaunas). 2022 Dec 19;58(12):1874. doi: 10.3390/medicina58121874.
2
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.18F-氟脱氧葡萄糖 PET/CT 扫描中最大标准摄取值(SUVmax)对恶性胸膜间皮瘤患者的预后价值。
PLoS One. 2020 Feb 18;15(2):e0229299. doi: 10.1371/journal.pone.0229299. eCollection 2020.
3
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.计算机断层扫描在恶性胸膜间皮瘤评估中的应用——肿瘤大小与肉瘤样组织学、更晚期的 TNM 分期和不良预后相关。
Lung Cancer. 2018 Feb;116:73-79. doi: 10.1016/j.lungcan.2018.01.001. Epub 2018 Jan 4.
4
Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?恶性胸膜间皮瘤:计算机断层扫描上是否存在与不同组织学亚型相关的影像学特征?
J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.
5
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.恶性胸膜间皮瘤患者中 PD-L1 高表达与肉瘤样或双相组织学亚型相关的生存期更短:来自 Bio-MAPS 队列的 214 例系列病例。
Clin Lung Cancer. 2019 Sep;20(5):e564-e575. doi: 10.1016/j.cllc.2019.04.010. Epub 2019 May 13.
6
[Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].[CD24基因在人恶性胸膜间皮瘤中的表达及其与预后的关系]
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2023 Mar 20;41(3):168-176. doi: 10.3760/cma.j.cn121094-20220228-00100.
7
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.新辅助化疗后正电子发射断层扫描代谢反应对可切除恶性胸膜间皮瘤的预后意义。
Ann Oncol. 2013 Apr;24(4):1005-10. doi: 10.1093/annonc/mds537. Epub 2012 Nov 7.
8
Clinicopathological features of radiological early malignant pleural mesothelioma with no apparent tumor or pleural thickening.影像学早期无明显肿瘤或胸膜增厚的恶性胸膜间皮瘤的临床病理特征。
Int J Clin Oncol. 2021 Jan;26(1):95-103. doi: 10.1007/s10147-020-01780-0. Epub 2020 Sep 10.
9
Prognostic value of pretreatment volume-based quantitative F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.基于容积的治疗前定量F-FDG PET/CT参数对恶性胸膜间皮瘤患者的预后价值
Eur J Radiol. 2017 Jan;86:176-183. doi: 10.1016/j.ejrad.2016.11.019. Epub 2016 Nov 15.
10
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.在评估恶性胸膜间皮瘤对铂类双联化疗的反应时,18F-FDG-PET/CT代谢反应评估优于改良RECIST标准。
Eur J Radiol. 2017 Jan;86:92-98. doi: 10.1016/j.ejrad.2016.11.009. Epub 2016 Nov 5.

引用本文的文献

1
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.胸膜间皮瘤:血液和胸膜生物标志物的进展
J Clin Med. 2023 Nov 9;12(22):7006. doi: 10.3390/jcm12227006.

本文引用的文献

1
The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值在慢性阻塞性肺疾病合并肺癌中的临床意义
Front Oncol. 2022 Sep 27;12:902955. doi: 10.3389/fonc.2022.902955. eCollection 2022.
2
Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer.术前全身炎症反应指数是预测非肌肉浸润性膀胱癌患者卡介苗免疫治疗预后的独立标志物。
Cancer Med. 2023 Feb;12(4):4206-4217. doi: 10.1002/cam4.5284. Epub 2022 Oct 10.
3
A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma.
正电子发射断层扫描/计算机断层扫描在恶性胸膜间皮瘤反应评估中的作用。
Semin Nucl Med. 2022 Nov;52(6):816-823. doi: 10.1053/j.semnuclmed.2022.04.008. Epub 2022 May 24.
4
A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer.一种用于预测肺癌免疫检查点抑制剂治疗后超进展性疾病的列线图。
Transl Lung Cancer Res. 2022 Apr;11(4):607-616. doi: 10.21037/tlcr-22-171.
5
One-Year Mortality in Patients with Cancer Cachexia: Association with Albumin and Total Protein.癌症恶病质患者的一年死亡率:与白蛋白和总蛋白的关联。
Cancer Manag Res. 2021 Aug 29;13:6775-6783. doi: 10.2147/CMAR.S318728. eCollection 2021.
6
Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.间皮瘤风险评分:一种用于恶性胸膜间皮瘤的新的预后预处理、临床-分子算法。
J Thorac Oncol. 2021 Nov;16(11):1925-1935. doi: 10.1016/j.jtho.2021.06.014. Epub 2021 Jul 6.
7
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review.恶性胸膜间皮瘤的免疫微环境:文献综述
Cancers (Basel). 2021 Jun 26;13(13):3205. doi: 10.3390/cancers13133205.
8
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade.炎症标志物和降钙素原可预测接受PD-1/PD-L1免疫检查点阻断治疗的转移性非小细胞肺癌患者的预后。
Front Oncol. 2021 Jun 14;11:684110. doi: 10.3389/fonc.2021.684110. eCollection 2021.
9
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤中肿瘤免疫微环境(TIME)的病理特征
Cancers (Basel). 2021 May 24;13(11):2564. doi: 10.3390/cancers13112564.
10
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.恶性胸膜间皮瘤:两所三级学术机构的基于手术的三联疗法与药物治疗的比较。
Lung Cancer. 2021 Jun;156:151-156. doi: 10.1016/j.lungcan.2021.04.025. Epub 2021 May 3.